VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, announced an update on its strategy to implement U.S. Food and Drug Administration-aligned New Approach Methodologies (NAMs) across its preclinical research and development programs. The company said the approach could accelerate clinical advancement, reduce development costs and timelines, and significantly reduce animal testing. This matters because it signals a potential shift in how cancer therapies are developed, aligning with regulatory trends toward more human-relevant testing while addressing ethical concerns about animal use.
VERAXA has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates, and bispecific antibody-drug conjugates. According to the company, its lead BiTAC-TCE and bsADC candidates were evaluated using an ex vivo panel of 10 low-passage patient-derived xenograft models of non-small cell lung cancer. The panel required about 10 mice in total, compared with an estimated 200 or more for comparable in vivo efficacy studies. Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, supporting the company's dual-targeting approach and demonstrating how its NAM strategy can reduce animal use and preclinical cycle time without compromising clinical relevance.
The implications of this announcement extend beyond animal welfare. By reducing reliance on animal models, VERAXA may be able to move its candidates into clinical trials more quickly and at lower cost, potentially bringing new cancer therapies to patients sooner. Moreover, the FDA has been encouraging the use of NAMs as part of its modernization efforts, and companies that successfully integrate these methods could gain a regulatory and competitive advantage. For investors, this update highlights VERAXA's commitment to innovation and efficiency in a challenging drug development landscape.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research and cutting-edge technology. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Its pipeline is powered by a suite of transformative technologies and guided by rigorous quality-by-design principles.
For more details on VERAXA's NAM strategy, see the full press release at https://ibn.fm/9YRJw. The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA. Additional information about VERAXA Biotech can be found at VERAXA Biotech (NASDAQ: VRXA).
Forward-looking statements in this article involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These statements are based on information available as of the date hereof, and all parties undertake no duty to update this information unless required by law. Undue reliance should not be placed on these forward-looking statements in making an investment decision.
